Investment Updates

When Covid hit, cruise ship stocks fell to pennies on the dollar. It was assumed by otherwise smart people that no one would ever get on a cruise ship again. Figuring this was hogwash, I bought a bunch of shares of the leading cruise company, Royal Caribbean, at $37/share. It's now up to $119, within easy reach of its pre-COVID high of $133.

I bear firmly in mind that I'm not out-smarting anyone. The moment one imagines oneself smarter than the geniuses will be recalled as the initiation point of one's inexorable ruin. I don't imagine for a second that I'm the only one who saw this play. I'm just one of the very few who played it.

Why? Because I'm not a professional money guy under insane pressure to show huge results each and every quarter. Nor am I a spastic day trader chasing home run returns this week. My superpower, for the nth time, is patience. When I bought in Spring, 2020, I had no idea when the snapback would occur, which meant parking my money for uncertain lengths of time, incurring opportunity costs. Very few people will do this. Only shitty small-timers. SSTs!

Unpressured, non-greedy, and not maniacally enthralled with my own savvy, I could mulishly let the investment simmer for a few years. And I did, scoring a 221% profit. That's less impressive given the 3.5 years of waiting, but it's more than good enough for a SST like me.

I'd let some of that investment ride, but I know nothing about cruise ships. It may reach $133 or even $1330, but I would not be plying my patience advantage, and raw ignorant hope is no investment strategy. So I'll sell here.


In other investment news...

Monkeypox is on the ups again in Asia (here and here). The disease is survivable, but it's an ugly affair that can leave you scarred. SIGA has made frustratingly little advancement in positioning its indisputably safe and effective smallpox drug for treatment, though doctors in the know have full faith in it. Here is the CDC nearly breaking decorum to wink, nod, and strain to convince practitioners to use SIGA's drug for monkeypox despite its sorrowful lack of approvals.

I recently predicted that Apple would obviously go to $200. Almost there! But if you bought this year, I'd urge holding for the long term gain (i.e. lower tax bill)....even if it means waiting for the cycle to repeat itself. Apple never fails to take random silly dives, but it also never fails to recover and shoot beyond before the next random silly dive.